Joseph F. Poduslo, Ph.D.

Location: Minnesota

Delivery of therapeutic proteins into the nervous system

Quantitative assessment of the permeability of peptides and proteins at the blood-brain barrier and blood-nerve barrier.

Protein modifications to increase permeability at the blood-brain barrier and blood-nerve barrier: glycation, polyamine modification (putrescine, spermine, spermidine), ubiquitin modification.

Delivery of therapeutic proteins across the blood-brain/nerve barriers after systemic administration for the treatment of neurodegenerative diseases.

Proteins targeted for delivery: neurotrophic factors, anti-oxidant enzymes (superoxide dismutase, catalase), leptin, peptides that inhibit amyloidogenesis, interferons, cytokines, antibodies, interleukins, etc.

Pre-clinical animal models to demonstrate efficacy of our delivery technology include:

Animal Models	Therapy
Transgenic mouse model of FALS with a point mutation of Gly 93 Ala in SOD	Antioxidant enzymes
Transgenic mouse models of Alzheimer's disease that overexpress human A βprotein	Peptides that inhibit amyloidogenesis, antioxidant enzymes, antibodies to A β
Obesity	Leptin
Diabetic neuropathy: Modulation of DRG trkA and p75 NGF receptors after peripheral axotomy	NGF
Four-vessel occlusion model of cerebral ischemia (stroke)	Anti-oxidant enzymes

Post Doctoral Fellowship – National Multiple Sclerosis Society
National Institutes of Health

Predoctoral Fellowship – (USPHSG), Institute of Neurological Sciences
University of Pennsylvania

Ph.D. – Biochemistry (Neurological Sciences)
University of Pennsylvania

B.A. – Chemistry
College of Wooster

Research Training –
Department of Neurology, Albert Einstein College of Medicine